Kala Pharmaceuticals, Inc. announced the following key commercial hires in preparation for the potential approval and launch of INVELTYSTM: Kathleen McCann Kline as Vice President of Marketing, James Patnoe as Vice President of Commercial Operations and Pricing; Carl Rennie as Executive Director of Account Management, Patrick Bedell as Executive Director of Trade and Alternate Channels and Lynette Zickl as Director of Commercial Analytics and Forecasting. Ms. Kline has joined Kala Pharmaceuticals as Vice President of Marketing. Most recently, she served as Vice President of Marketing for the Ophthalmology and Women’s Health divisions at Bausch and Lomb where she was instrumental in leading the strategic initiatives supporting numerous surgical and pharmaceutical franchises, including intraocular lenses, surgical equipment and the Loteprednol franchise. Mr. Patnoe has joined Kala Pharmaceuticals as Vice President of Commercial Operations and Pricing. Previously, he served as Vice President of Sales Operations, Contracts and Pricing at Takeda Pharmaceuticals America, where he spent 10 years in roles of increasing responsibility, including Vice President of Managed Markets. Mr. Rennie has joined Kala Pharmaceuticals as Executive Director of Account Management. Prior to Kala, he was the Director of National Accounts for Collegium Pharmaceuticals. Mr. Bedell has joined Kala Pharmaceuticals as Executive Director of Trade and Alternate Channels. Most recently, he was Senior Director of Trade and Alternate Channels for Collegium Pharmaceuticals. Ms. Zickl has joined Kala Pharmaceuticals as Director of Commercial Analytics and Forecasting. Previously, she was Head of Insights and Analytics for scPharmaceuticals, where she led the Commercial Analytics and Operations build-out and helped the company transition from Series A to a publicly-traded company.